RU2012122700A - Структура сокристалла фактора d и антитела к фактору d - Google Patents

Структура сокристалла фактора d и антитела к фактору d Download PDF

Info

Publication number
RU2012122700A
RU2012122700A RU2012122700/10A RU2012122700A RU2012122700A RU 2012122700 A RU2012122700 A RU 2012122700A RU 2012122700/10 A RU2012122700/10 A RU 2012122700/10A RU 2012122700 A RU2012122700 A RU 2012122700A RU 2012122700 A RU2012122700 A RU 2012122700A
Authority
RU
Russia
Prior art keywords
factor
polypeptide
antibody
crystal
seq
Prior art date
Application number
RU2012122700/10A
Other languages
English (en)
Russian (ru)
Inventor
Менно Ван Локерен КАМПАГНЕ
Кристиан ВИСМАНН
Original Assignee
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. filed Critical Дженентек, Инк.
Publication of RU2012122700A publication Critical patent/RU2012122700A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2299/00Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
RU2012122700/10A 2009-11-04 2010-11-04 Структура сокристалла фактора d и антитела к фактору d RU2012122700A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28046009P 2009-11-04 2009-11-04
US61/280,460 2009-11-04
US28171609P 2009-11-20 2009-11-20
US61/281,716 2009-11-20
PCT/US2010/055509 WO2011057014A1 (en) 2009-11-04 2010-11-04 Co-crystal structure of factor d and anti-factor d antibody

Publications (1)

Publication Number Publication Date
RU2012122700A true RU2012122700A (ru) 2013-12-10

Family

ID=43303899

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012122700/10A RU2012122700A (ru) 2009-11-04 2010-11-04 Структура сокристалла фактора d и антитела к фактору d

Country Status (14)

Country Link
US (1) US20110165648A1 (cg-RX-API-DMAC7.html)
EP (1) EP2496695A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013509866A (cg-RX-API-DMAC7.html)
KR (1) KR20120120153A (cg-RX-API-DMAC7.html)
CN (1) CN102666850A (cg-RX-API-DMAC7.html)
AR (1) AR078886A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012011607A2 (cg-RX-API-DMAC7.html)
CA (1) CA2782481A1 (cg-RX-API-DMAC7.html)
IN (1) IN2012DN03338A (cg-RX-API-DMAC7.html)
MX (1) MX2012005430A (cg-RX-API-DMAC7.html)
RU (1) RU2012122700A (cg-RX-API-DMAC7.html)
TW (1) TW201121993A (cg-RX-API-DMAC7.html)
WO (1) WO2011057014A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201202602B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170001A (es) * 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
KR20180021234A (ko) 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
JP2017515811A (ja) 2014-05-01 2017-06-15 ジェネンテック, インコーポレイテッド 抗d因子抗体変異体及びその使用法
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016061562A2 (en) 2014-10-17 2016-04-21 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
AU2016344133A1 (en) * 2015-10-30 2018-05-17 Genentech, Inc. Anti-Factor D antibody formulations
CN108289951A (zh) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
EP3405577B8 (en) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions and methods for inhibiting factor d
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
CA3059938A1 (en) * 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク,インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
US6291160B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
KR0185192B1 (ko) 1989-10-05 1999-04-01 제임스 더블유. 데이비 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리
US5244800A (en) * 1990-04-27 1993-09-14 The Uab Research Foundation Crystals of human complement factor d that are triclinic
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
JP2010508819A (ja) * 2006-11-02 2010-03-25 ジェネンテック インコーポレイテッド ヒト化抗d因子抗体
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) * 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados

Also Published As

Publication number Publication date
BR112012011607A2 (pt) 2020-06-02
KR20120120153A (ko) 2012-11-01
IN2012DN03338A (cg-RX-API-DMAC7.html) 2015-10-23
JP2013509866A (ja) 2013-03-21
TW201121993A (en) 2011-07-01
ZA201202602B (en) 2013-06-26
CN102666850A (zh) 2012-09-12
CA2782481A1 (en) 2011-05-12
EP2496695A1 (en) 2012-09-12
AR078886A1 (es) 2011-12-07
WO2011057014A1 (en) 2011-05-12
MX2012005430A (es) 2012-06-19
US20110165648A1 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
RU2012122700A (ru) Структура сокристалла фактора d и антитела к фактору d
Yamamoto et al. Self-reported sleep duration and prediction of proteinuria: a retrospective cohort study
US20240043507A1 (en) Antibodies
RU2013152816A (ru) АНТИТЕЛО ПРОТИВ ПРОТЕИНТИРОЗИНФОСФАТАЗЫ σ РЕЦЕПТОРНОГО ТИПА ЧЕЛОВЕКА
RU2012110578A (ru) Способы и композиции для лечения фиброзных заболеваний легких
Schiffner et al. Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins
WO2014170312A1 (en) Piiinp neo-epitope assay
Park et al. Comparison of transthoracic echocardiography with N-terminal pro-brain natriuretic peptide as a tool for risk stratification of patients undergoing major noncardiac surgery
WO2020245404A1 (en) Assay for assessing heart failure
CN108431606B (zh) 纤维化的联合生物标志物测量
Kongsaree et al. Skeletal effect of parathyroidectomy on patients with primary hyperparathyroidism: a systematic review and meta-analysis
Kauko et al. Iron incorporation in Streptococcus suis Dps-like peroxide resistance protein Dpr requires mobility in the ferroxidase center and leads to the formation of a ferrihydrite-like core
Reese-Petersen et al. Evaluation of a novel biomarker of type XXVIII collagen formation, PRO-C28, in samples from cancer and heart failure with preserved ejection fraction patients
KR20180102647A (ko) 콜라겐 타입 vii 알파 1 분석
US8645083B2 (en) Method to screen high affinity antibody
WO2015032776A1 (en) Method for improving antibody stability
EP3886898A1 (en) Recombinant hiv env polypeptides and their use
Baessler et al. Adiponectin multimeric forms but not total adiponectin levels are associated with myocardial infarction in non-diabetic men
Elbarbary et al. Point‐of‐Care Tests for Preeclampsia: Systematic Review and Meta‐Analysis of Diagnostic Test Accuracy Studies
WO2019129679A1 (en) Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
US20190079080A1 (en) Antibody specific to profilaggrin c-terminal domain, and use thereof
Hoshi et al. Surface X-ray scattering of high index plane of platinum containing kink atoms in solid–liquid interface: Pt (3 1 0)= 3 (1 0 0)–(1 1 0)
Liu et al. The Association between Percentage of Mean Arterial Pressure and Long-Term Mortality in Acute Myocardial Infarction Patients: An Observational Cohort Study
WO2022117526A1 (en) Il-7 binding proteins and their use in medical therapy
Imai et al. Development of a novel immunoassay specific for mouse intact proinsulin

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20131105